Literature DB >> 33165145

NLRP3 Inflammasome: A New Promising Therapeutic Target to Treat Heart Failure.

Marco G Del Buono1,2, Filippo Crea1,2, Francesco Versaci3, Giuseppe Biondi-Zoccai4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33165145     DOI： 10.1097/FJC.0000000000000946

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN： 0160-2446            Impact factor:   3.105


× No keyword cloud information.
  4 in total

1.  Hydrogen Attenuates Myocardial Injury in Rats by Regulating Oxidative Stress and NLRP3 Inflammasome Mediated Pyroptosis.

Authors:  Hongxiao Yang; Shuang Liu; Huijun Du; Zi Hong; Yajing Lv; Chaoqun Nie; Wei Yang; Yunan Gao
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

2.  MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice.

Authors:  Menglong Wang; Mengmeng Zhao; Junping Yu; Yao Xu; Jishou Zhang; Jianfang Liu; Zihui Zheng; Jing Ye; Zhen Wang; Di Ye; Yongqi Feng; Shuwan Xu; Wei Pan; Cheng Wei; Jun Wan
Journal:  Front Cardiovasc Med       Date:  2022-05-12

Review 3.  Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.

Authors:  Peng Kong; Zi-Yang Cui; Xiao-Fu Huang; Dan-Dan Zhang; Rui-Juan Guo; Mei Han
Journal:  Signal Transduct Target Ther       Date:  2022-04-22

4.  Cardioprotective Antioxidant and Anti-Inflammatory Mechanisms Induced by Intermittent Hypobaric Hypoxia.

Authors:  Alejandro González-Candia; Alejandro A Candia; Adolfo Paz; Fuad Mobarec; Rodrigo Urbina-Varela; Andrea Del Campo; Emilio A Herrera; Rodrigo L Castillo
Journal:  Antioxidants (Basel)       Date:  2022-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.